3 months ago
BCRX
AnalystsJonathan WollebenJonathan Wolleben's Stock Forecasts
AnalystsJonathan Wolleben
Analyst Ranking
Top 3%
#119 out of 5197 analysts
Average Return
+21.45%
Win Rate
51%123 out of 242
Risk vs Reward
Poor
Good
Jonathan Wolleben's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Mbx Biosciences IncMBX | +542.90% | $6.27 | $40.31 | 2025-04-09 - 2026-02-18 | Buy |
Dbv Technologies SaDBVT | +397.39% | $3.45 | $17.16 | 2024-12-09 - 2025-12-09 | Buy |
Dbv Technologies SaDBVT | +377.91% | $4.30 | $20.55 | 2025-03-03 - 2026-02-18 | Buy |
Madrigal Pharmaceuticals IncMDGL | +365.01% | $64.44 | $299.65 | 2022-05-09 - 2023-05-09 | Buy |
Structure Therapeutics IncGPCR | +321.98% | $16.20 | $68.36 | 2025-08-06 - 2026-02-18 | Buy |
Jonathan Wolleben Analyst Color
Get additional color on Jonathan Wolleben's coverage of popular stocks
4 months ago
BCRX
a year ago
SPOT
Jonathan Wolleben's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | 13 | Buy | $745.00 | +51.58% | Maintains | a month ago |
Crinetics Pharmaceuticals IncCRNX | 18 | Buy | $105.00 | +141.66% | Maintains | a month ago |
Mirum Pharmaceuticals IncMIRM | 13 | Buy | $140.00 | +33.21% | Maintains | 2 months ago |
Dbv Technologies SaDBVT | 16 | Buy | $45.00 | +118.98% | Maintains | 2 months ago |
Rhythm Pharmaceuticals IncRYTM | 6 | Buy | $167.00 | +64.86% | Maintains | 2 months ago |
Structure Therapeutics IncGPCR | 11 | Buy | $120.00 | +75.54% | Maintains | 2 months ago |
Sagimet Biosciences IncSGMT | 9 | Buy | $35.00 | +566.67% | Maintains | 3 months ago |
Savara IncSVRA | 10 | Buy | $10.00 | +78.89% | Maintains | 3 months ago |
Spruce Biosciences IncSPRB | 8 | Buy | $259.00 | +384.29% | Maintains | 3 months ago |
Kalvista Pharmaceuticals IncKALV | 6 | Buy | $28.00 | +81.23% | Maintains | 3 months ago |
Protagonist Therapeutics IncPTGX | 13 | Buy | $102.00 | +22.91% | Maintains | 3 months ago |
Altimmune IncALT | 13 | Buy | $14.00 | +213.90% | Maintains | 3 months ago |
Biocryst Pharmaceuticals IncBCRX | 10 | Buy | $25.00 | +244.35% | Maintains | 3 months ago |
Kalaris Therapeutics IncKLRS | 1 | Buy | $20.00 | +95.31% | Initiates Coverage On | 4 months ago |
Ocular Therapeutix IncOCUL | 16 | Buy | $29.00 | +321.51% | Maintains | 5 months ago |
Larimar Therapeutics IncLRMR | 13 | Buy | $18.00 | +510.17% | Reiterates | 6 months ago |
Pharvaris NvPHVS | 12 | Buy | $52.00 | +92.52% | Maintains | 6 months ago |
Astria Therapeutics IncATXS | 3 | Buy | $26.00 | +106.68% | Maintains | 6 months ago |
Quince Therapeutics IncQNCX | 2 | Buy | $8.00 | +4,394.38% | Maintains | 6 months ago |
Proqr Therapeutics NvPRQR | 6 | Buy | $8.00 | +436.91% | Reiterates | 8 months ago |
Skye Bioscience IncSKYE | 3 | Buy | $15.00 | +1,815.71% | Reiterates | 8 months ago |
Aura Biosciences IncAURA | 9 | Buy | $19.00 | +276.98% | Reiterates | 9 months ago |
Clearside Biomedical IncCLSDQ | 11 | Buy | $75.00 | +18,192.68% | Reiterates | 9 months ago |
Mbx Biosciences IncMBX | 1 | Buy | $38.00 | -5.73% | Initiates Coverage On | 10 months ago |
Hilton Grand Vacations IncHGV | 1 | Buy | $50.00 | N/A | Maintains | a year ago |
Costar Group IncCSGP | 1 | Buy | $90.00 | N/A | Reiterates | a year ago |
Spotify Technology SaSPOT | 1 | Buy | $485.00 | N/A | Downgrades | a year ago |
Allakos IncALLK | 6 | Buy | $3.00 | N/A | Reiterates | a year ago |
Rallybio CorpRLYB | 11 | Buy | $64.00 | N/A | Reiterates | 2 years ago |
Warner Music Group CorpWMG | 1 | Buy | $24.00 | N/A | Maintains | 3 years ago |
Strongbridge Biopharma PLCSBBP | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.